fashion -WSS

fashion

author：focus 2025-10-01 05:38:19 - browse：8

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Rep. Raul Ruiz on the physician shortage and more

knowledge

focus

knowledge

WSS

Takeda, Janssen join wearable maker to measure scratching

ReNAgade cuts staff seven months after raising $300 million

How a symptom of dementia informs our understanding of creativity

The EPA's new lead rule: How one expert crunched the numbers

Why more medical students aren't specializing in primary care

Fetal surgery at risk from Dobbs and new abortion restrictions

hotspot

fashion

entertainment

Hollywood unions extend contract negotiations for actors

Mayo Clinic plans $5B tech

Moonlake's readout produced a cash windfall. Risks remain

How to make Best Hospitals ratings actually useful for patients

23andMe had bad news about my health. I wish a person had delivered it

Radiation, mainstay of cancer treatment, begins a fade

Moonlake's readout produced a cash windfall. Risks remain

How a symptom of dementia informs our understanding of creativity

What does generative AI mean for health care? We asked experts

U.K. Biobank has 500,000 peoples' genome sequences available

focus

Winners, losers from Medicare’s list of drugs subject to price talks

Cigna, Humana reportedly in talks to merge

Departing Stanford president retracts two papers

Despite FDA concern, risk that CAR

How to make AI work for medicine

Complete sequence of Y chromosome published for first time

knowledge

focus

knowledge

entertainment